Back to search

Article

Omission of Chemotherapy in HR+/HER2- Early Invasive Breast Cancer Based on Combined 6-IHC Score?

2020-05-26

Abstract excerpt

<title>Abstract</title> <p>Background: Previous randomized studies have assessed the possibility of omission of chemotherapy in some hormone receptor (HR)-positive and HER2-negative (HR+/HER2-) breast cancers (BC) based on gene profiling test, e.g., Oncotype DX. The goal of this study was to evaluate if combination of six proliferation related biomarkers by immunohistochemistry (6-IHC) could be a cost-effective o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5732667c-66a0-5042-98ce-eebb5913b3a6
DOI
10.21203/rs.3.rs-30455/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Omission of Chemotherapy in HR+/HER2- Early Invasive Breast Cancer Based on Combined 6-IHC Score?DOI 10.21203/rs.3.rs-30455/v1
Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity
Prognostic Predictors Do Not Equate to Predictors of Chemotherapy Benefit in HR-Positive, HER2-Negative Breast Cancer: A Population-Based StudySemantic proximity
The relationship between hormone receptor status, tumor size and clinical stage and the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer, predictors of survival, and the establishment of Cox-Based risk prediction model and nomogramSemantic proximity
Novel Prognostic Stratification and Therapeutic Implications in T1N0M0 Breast Cancer: Insights from a Multi-Center Chinese CohortSemantic proximity
Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterationsSemantic proximity
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity
Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity
Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity
Risk Evaluation of Early-stage Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Patients: a Population-based Study From TaiwanSemantic proximity
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity
Select a neighboring publication to make it the new centre.